Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors (Q39308117)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Jingxian Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Jia Jia

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Feng Zhu

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Xiaohua Ma

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Bucong Han

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Xiaona Wei

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Chunyan Tan

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Yuyang Jiang

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Yuzong Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

1 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Molecular BioSystems

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2645-2656

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

EGFR-directed therapies to treat non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Mutations and response to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Integrating molecular diagnostics into anticancer drug discovery.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cancer: mixing cocktails.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Targeting the cancer kinome through polypharmacology

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Targeting multiple kinase pathways: a change in paradigm

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Microarray data analysis: from disarray to consolidation and consensus

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Derivation of stable microarray cancer-differentiating signatures using consensus scoring of multiple random sampling and gene-ranking consistency evaluation.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

DNA microarrays are predictive of cancer prognosis: a re-evaluation

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Chemosensitivity prediction by transcriptional profiling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Predicting cancer drug response by protoeomic profiling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Prediction of anticancer drug potency from expression of genes involved in growth factor signaling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Chemical data mining of the NCI human tumor cell line database

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Outgrowth of single oncogene-expressing cells from suppressive epithelial environments.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The ras gene family and human carcinogenesis

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cancer-specific mutations in PIK3CA are oncogenic in vivo

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Rare cancer-specific mutations in PIK3CA show gain of function

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

EGFR and beta1 integrins utilize different signaling pathways to activate Akt.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

KRAS mutations predict response to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The Tumor Microenvironment in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

A five-gene signature and clinical outcome in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The ERBB3 receptor in cancer and cancer gene therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gene name ambiguity of eukaryotic nomenclatures

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Status of text-mining techniques applied to biomedical text

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The influence of feature selection methods on accuracy, stability and interpretability of molecular signatures

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Next-generation DNA sequencing

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Microarrays and high-throughput transcriptomic analysis in species with incomplete availability of genomic sequences.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Systematic assessment of copy number variant detection via genome-wide SNP genotyping

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Robust biomarker identification for cancer diagnosis with ensemble feature selection methods

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Database resources of the National Center for Biotechnology Information: update

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The Universal Protein Resource (UniProt) 2009

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

A crowdsourcing evaluation of the NIH chemical probes

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

NCBI GEO: archive for functional genomics data sets--10 years on

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

ABC efflux pump-based resistance to chemotherapy drugs.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Global variation in copy number in the human genome

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Statistical intelligence: effective analysis of high-density microarray data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Gene Selection for Cancer Classification using Support Vector Machines

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Systematic benchmarking of microarray data classification: assessing the role of non-linearity and dimensionality reduction

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Ensemble dependence model for classification and prediction of cancer and normal gene expression data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Analysis of recursive gene selection approaches from microarray data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Filter versus wrapper gene selection approaches in DNA microarray domains

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB25165E

21 January 2018

Identifiers

10.1039/C2MB25165E

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39308117&oldid=1819483873"